.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
US Department of Justice
Argus Health
Cantor Fitzgerald
AstraZeneca
Express Scripts
Baxter
QuintilesIMS
Medtronic
Accenture

Generated: December 18, 2017

DrugPatentWatch Database Preview

Ge Healthcare Company Profile

« Back to Dashboard

What is the competitive landscape for GE HEALTHCARE, and when can generic versions of GE HEALTHCARE drugs launch?

GE HEALTHCARE has fifty-five approved drugs.

There are six US patents protecting GE HEALTHCARE drugs.

There are one hundred and five patent family members on GE HEALTHCARE drugs in thirty countries and sixty-nine supplementary protection certificates in fifteen countries.

Summary for Ge Healthcare

International Patents:105
US Patents:6
Tradenames:61
Ingredients:43
NDAs:55
Drug Master File Entries: 5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge HealthcareOMNISCANgadodiamideINJECTABLE;INJECTION022066-002Sep 5, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ge HealthcareNEOSCANgallium citrate ga-67INJECTABLE;INJECTION017655-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge HealthcareHYPAQUEdiatrizoate meglumineINJECTABLE;INJECTION016403-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge HealthcareHYPAQUEdiatrizoate meglumineINJECTABLE;INJECTION016403-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge HealthcareMPI INDIUM DTPA IN 111indium in-111 pentetate disodiumINJECTABLE;INTRATHECAL017707-001Feb 18, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Ge HealthcareTC 99M-LUNGAGGREGATEtechnetium tc-99m albumin aggregatedINJECTABLE;INJECTION017848-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge HealthcareMETASTRONstrontium chloride sr-89INJECTABLE;INJECTION020134-001Jun 18, 1993APRXYesYes► Subscribe► Subscribe► Subscribe
Ge HealthcareOMNIPAQUE 240iohexolSOLUTION;INJECTION, ORAL, RECTAL018956-002Dec 26, 1985RXYesYes► Subscribe► Subscribe► Subscribe
Ge HealthcareHYPAQUE SODIUM 20%diatrizoate sodiumSOLUTION;URETERAL009561-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge HealthcareVISIPAQUE 320iodixanolINJECTABLE;INJECTION020808-002Aug 29, 1997► Subscribe► Subscribe
Ge HealthcareTESLASCANmangafodipir trisodiumINJECTABLE;INJECTION020652-001Nov 26, 1997► Subscribe► Subscribe
Ge HealthcareVISIPAQUE 320iodixanolINJECTABLE;INJECTION020808-002Aug 29, 1997► Subscribe► Subscribe
Ge HealthcareOMNIPAQUE 350iohexolSOLUTION;INJECTION, ORAL018956-004Dec 26, 1985► Subscribe► Subscribe
Ge HealthcareOMNIPAQUE 180iohexolSOLUTION;INJECTION, ORAL, RECTAL018956-001Dec 26, 1985► Subscribe► Subscribe
Ge HealthcareMYOVIEWtechnetium tc-99m tetrofosmin kitINJECTABLE;INJECTION020372-001Feb 9, 1996► Subscribe► Subscribe
Ge HealthcareOMNISCANgadodiamideINJECTABLE;INJECTION020123-001Jan 8, 1993► Subscribe► Subscribe
Ge HealthcareVISIPAQUE 270iodixanolINJECTABLE;INJECTION020808-001Aug 29, 1997► Subscribe► Subscribe
Ge HealthcareOMNIPAQUE 350iohexolSOLUTION;INJECTION, ORAL018956-004Dec 26, 1985► Subscribe► Subscribe
Ge HealthcareVISIPAQUE 270iodixanolINJECTABLE;INJECTION020808-001Aug 29, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Ge Healthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,620,404 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media► Subscribe
8,911,707Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
5,558,854 Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas► Subscribe
6,156,292 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media► Subscribe
5,393,524 Methods for selecting and using gases as ultrasound contrast media► Subscribe
9,134,328Methods of using benzothiazole derivative compounds and compositions► Subscribe
6,875,420 Method of ultrasound imaging► Subscribe
5,573,751 Persistent gaseous bubbles as ultrasound contrast media► Subscribe
9,808,541Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
8,404,213Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ge Healthcare Drugs

Country Document Number Estimated Expiration
Norway313577► Subscribe
Russian Federation2324686► Subscribe
Japan2001026554► Subscribe
World Intellectual Property Organization (WIPO)2004083195► Subscribe
Japan2006522104► Subscribe
Norway2015006► Subscribe
Denmark0605477► Subscribe
Norway330861► Subscribe
Portugal100867► Subscribe
Greece3033908► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ge Healthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0006France► SubscribePRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
C0101Belgium► SubscribePRODUCT NAME: IODIXANOL; NAT. REGISTRATION NO/DATE: 914 IS 204 F 12 19970325; FIRST REGISTRATION: SE 11758 19930205
C/GB07/011United Kingdom► SubscribePRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
C/GB02/042United Kingdom► SubscribePRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418
15/004Ireland► SubscribePRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
C0052France► SubscribePRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
2008006,C0933372Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
C0041France► SubscribePRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
14/032Ireland► SubscribePRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Accenture
Daiichi Sankyo
Merck
Baxter
Cantor Fitzgerald
McKesson
Cipla
QuintilesIMS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot